CA3291532A1 - Adjuvants de vaccin - Google Patents

Adjuvants de vaccin

Info

Publication number
CA3291532A1
CA3291532A1 CA3291532A CA3291532A CA3291532A1 CA 3291532 A1 CA3291532 A1 CA 3291532A1 CA 3291532 A CA3291532 A CA 3291532A CA 3291532 A CA3291532 A CA 3291532A CA 3291532 A1 CA3291532 A1 CA 3291532A1
Authority
CA
Canada
Prior art keywords
vaccine adjuvants
vaccine
adjuvants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3291532A
Other languages
English (en)
Inventor
Douglas G. WIDMAN
Palaniappan Ramanathan
Original Assignee
Seqirus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus Inc filed Critical Seqirus Inc
Publication of CA3291532A1 publication Critical patent/CA3291532A1/fr
Pending legal-status Critical Current

Links

CA3291532A 2023-05-12 2024-05-13 Adjuvants de vaccin Pending CA3291532A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63/501,718 2023-05-12

Publications (1)

Publication Number Publication Date
CA3291532A1 true CA3291532A1 (fr) 2024-11-21

Family

ID=

Similar Documents

Publication Publication Date Title
EP4213872A4 (fr) Vaccin à base de piv5 contre la covid-19
EP4140501A4 (fr) Vaccin peptidique amélioré
CA3291532A1 (fr) Adjuvants de vaccin
AU2025905871A0 (en) Vaccine adjuvants
AU2022234358A1 (en) Polysaccharide adjuvants for virus vaccines
CA3298228A1 (fr) Vaccin
CA3280273A1 (fr) Vaccin
CA3290049A1 (fr) Vaccin contenant une chimère tp0751
HK40123327A (en) Vaccine
CA3268944A1 (fr) Vaccin
CA3270422A1 (fr) Vaccin amélioré
CA3291298A1 (fr) Vaccin combiné
HK40129738A (en) Glycoprotein d variants as vaccine adjuvants
CA3279505A1 (fr) Variants de glycoprotéine d utiles en tant qu'adjuvants de vaccin
EP4316511A4 (fr) Vaccin enrobé de nanogel
EP4284423A4 (fr) Vaccin
AU2021903076A0 (en) SARS-CoV2 Vaccine
AU2023902599A0 (en) Vaccine Antigen
AU2021902530A0 (en) Vaccine Antigen
AU2021902500A0 (en) Vaccine Antigen
HK40065844A (en) Vaccine adjuvants and formulations
HK40083308A (en) Vaccine formulations
AU2021900212A0 (en) Sars-CoV-2 vaccine antigens
CA3292453A1 (fr) Composés et formulations utiles comme adjuvants de vaccins
GB202204323D0 (en) Adjuvants